NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $4.41 -0.47 (-9.63%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$4.34 -0.07 (-1.47%) As of 04/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Xeris Biopharma Stock (NASDAQ:XERS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$4.28▼$4.7350-Day Range$3.47▼$5.8752-Week Range$1.69▼$6.07Volume3.87 million shsAverage Volume1.81 million shsMarket Capitalization$678.88 millionP/E RatioN/ADividend YieldN/APrice Target$6.10Consensus RatingModerate Buy Company OverviewXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Read More… Remove Ads Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreXERS MarketRank™: Xeris Biopharma scored higher than 85% of companies evaluated by MarketBeat, and ranked 130th out of 902 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingXeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXeris Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -9.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -9.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Xeris Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.88% of the float of Xeris Biopharma has been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 5.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.57 Percentage of Shares Shorted7.88% of the float of Xeris Biopharma has been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 5.46%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.21 News SentimentXeris Biopharma has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Xeris Biopharma this week, compared to 2 articles on an average week.Search Interest15 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat Follows7 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,200.00 in company stock.Percentage Held by InsidersOnly 4.56% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Stock News HeadlinesXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 6, 2025 | Premier Gold Co (Ad)12 Best Stocks to Invest in for a Stock Market GameMarch 20, 2025 | insidermonkey.comXeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market GameMarch 19, 2025 | insidermonkey.comCalculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 18, 2025 | finance.yahoo.comFDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aidMarch 17, 2025 | markets.businessinsider.comXeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic AidMarch 17, 2025 | finance.yahoo.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $3.39 at the beginning of 2025. Since then, XERS shares have increased by 30.1% and is now trading at $4.41. View the best growth stocks for 2025 here. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business earned $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD). Company Calendar Last Earnings8/08/2024Today4/06/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Stock Price Target$6.10 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+38.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,260,000.00 Net Margins-33.69% Pretax Margin-35.02% Return on EquityN/A Return on Assets-17.38% Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio1.29 Sales & Book Value Annual Sales$203.07 million Price / Sales3.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-88.20Miscellaneous Outstanding Shares153,940,000Free Float142,283,000Market Cap$678.88 million OptionableOptionable Beta1.37 Social Links 10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free Report This page (NASDAQ:XERS) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.